Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as ...
APPLY-PNH extension data show that continuous Fabhalta® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled...
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis...
Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement ...
Novartis is conducting a voluntary nationwide recall at the consumer level of two lots of its Sandimmune® Oral Solution (cyclosporine oral solution,...
Novartis, a global leader in immuno-dermatology and rheumatology, announced today that the US Food and Drug Administration (FDA) has approved...
Novartis, a global leader in immuno-dermatology and rheumatology, announced today that the US Food and Drug Administration (FDA) has approved an...
Novartis is conducting a voluntary nationwide recall at the consumer level of one lot of its Sandimmune® Oral Solution (cyclosporine oral solution,...
Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density...
Advarra, Virb and BeeKeeperAI sign on to Beacon of Hope to provide suite of digital tools to facilitate clinical trials and research on healthcare...
Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran) to enable earlier use in ...
Produced in partnership with advocate, journalist and filmmaker Jasmine IVANNA Espy, "The Beacons: Illuminating HS Stories" offers an intimate look...
Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with...
The ALITHIOS open-label extension study showed continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis...
Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1...
Trial met both primary and most secondary endpoints, showing iptacopan provided transfusion-free hemoglobin-level increases in vast majority of adult ...
Phase III APPOINT-PNH study of investigational oral monotherapy iptacopan met its primary endpoint; second positive Phase III topline readout for...
RIGHT Choice Phase II trial is the first randomized study in patients with aggressive HR+/HER2− metastatic breast cancer (MBC), including visceral...
Novartis commits additional $17.7 million to create Clinical Trial Centers of Excellence at Howard University College of Medicine, Meharry Medical...
Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a...
FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive...
Novartis, a leader in rheumatology and immuno-dermatology, today announced the US Food and Drug Administration (FDA) has approved Cosentyx®...
- Con dos dosis de mantenimiento al año, Leqvio es el primer y único tratamiento de ARN de interferencia pequeño (ARNip) aprobado por la FDA para la...
Novartis 今天宣布,美国食品药品监督管理局 (FDA) 批准 Leqvio® (inclisiran),这是第一款也是唯一一款用于降低低密度脂蛋白胆固醇(也称为坏胆固醇或 LDL-C)的小干扰 RNA (siRNA) 疗法,在给予初始剂量和第三个月的一剂给药后,可每年两次给药。...
Novartis 今日宣布美國食品藥物管理局(FDA)核准 Leqvio® (inclisiran),這是第一個也是唯一一個小型干擾 RNA(siRNA)療法,用於降低低密度脂蛋白膽固醇(也稱為壞膽固醇或 LDL-C),在初始劑量和三個月後再給予一劑之後,每年僅需兩劑。 Novartis 總裁...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.